Аннотации:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature. It is common knowledge that Candida albicans are one of the main sources of fungal infections which may lead to inflammation or even threaten life. Until now, fungal infection treatment has been considered as a challenging task due to several problems associated with their application like toxicity, drug interactions, and resistance. This paper outlines a new approach to develop effective agents against Candida albicans biofilms. The impact of borneols and sulfur-containing terpenoids of bornane series on the in vitro formation and growth of clinical strain of C. albicans in biofilms has been studied and compared with modern antimycotics. As a result, thioterpenoid 4 minimum inhibitory concentrations for C. albicans strain plankton ranged from 100 to 200 μg/ml where biofilm growth inhibition occurred at the concentration of 200 μg/ml. It is generally accepted that fluconazole 7 is widely used in clinical practice but still not effective against biofilms of C. albicans fungi. Therefore, we believe that isoborneol 2 and thioterpenoids 3 and 4, as well as terbinafine 6, can be promising starting points for the development of new antifungal agents against the pathogenic activity of fungi including pathogens embedded in biofilms since they demonstrated an effective resistance against the formation of pseudomycelia.
